Literature DB >> 10348224

Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand.

S Looareesuwan1, P Wilairatana, K Chalermarut, Y Rattanapong, C J Canfield, D B Hutchinson.   

Abstract

The increasing frequency of therapeutic failures in falciparum malaria underscores the need for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and proguanil are blood schizonticides that demonstrate synergistic activity against multi-drug-resistant Plasmodium falciparum in vitro. In an open-label, randomized, controlled clinical trial conducted in Thailand, adult patients with acute P. falciparum malaria were randomly assigned to treatment with atovaquone and proguanil/hydrochloride (1,000 mg and 400 mg, respectively, administered orally at 24-hr intervals for three doses) or mefloquine (750 mg administered orally, followed 6 hr later by an additional 500-mg dose). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was assessed by sequential clinical and laboratory assessments for 28 days. Atovaquone/proguanil was significantly more effective than mefloquine (cure rate 100% [79 of 79] vs. 86% [68 of 79]; P < 0.002). The atovaquone/proguanil and mefloquine treatments did not differ with respect to PCT (mean = 65 hr versus 74 hr) or FCT (mean = 59 hr versus 51 hr). Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group. Transient elevations of liver enzyme levels occurred more frequently in patients treated with atovaquone/proguanil than with mefloquine, but the differences were not significant and values returned to normal by day 28 in most patients. The combination of atovaquone and proguanil was well tolerated and more effective than mefloquine in the treatment of acute uncomplicated multidrug-resistant falciparum malaria in Thailand.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348224     DOI: 10.4269/ajtmh.1999.60.526

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

Review 1.  Antiparasitic agent atovaquone.

Authors:  Aaron L Baggish; David R Hill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.

Authors:  Andrew Blanshard; Paul Hine
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

3.  Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria.

Authors:  Giancarlo A Biagini; Parnpen Viriyavejakul; Paul M O'neill; Patrick G Bray; Stephen A Ward
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 4.  Management of malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Nanthaphorn Phophak; Sornchai Looareesuwan
Journal:  Korean J Parasitol       Date:  2002-03       Impact factor: 1.341

Review 5.  Atovaquone-proguanil for treating uncomplicated malaria.

Authors:  A Osei-Akoto; L Orton; S P O Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

6.  Biguanide-atovaquone synergy against Plasmodium falciparum in vitro.

Authors:  K Jones; S A Ward
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

Authors:  Ana Afonso; Zoraima Neto; Helena Castro; Dinora Lopes; Ana C Alves; Ana M Tomás; Virgílio D Rosário
Journal:  Malar J       Date:  2010-05-21       Impact factor: 2.979

Review 8.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Recent Advances and New Challenges in Travel Medicine.

Authors:  Lin H. Chen; Mary E. Wilson
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

10.  A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.

Authors:  James S McCarthy; Silvana Sekuloski; Paul M Griffin; Suzanne Elliott; Nanette Douglas; Chris Peatey; Rebecca Rockett; Peter O'Rourke; Louise Marquart; Cornelius Hermsen; Stephan Duparc; Jörg Möhrle; Katharine R Trenholme; Andrew J Humberstone
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.